Characteristics of OBRI participants at the time of enrolment. Values are mean ± SD or n (%) unless otherwise specified.
| Characteristics | n = 469 |
|---|---|
| Sociodemographic characteristics | |
| Age, yrs | 56.8 ± 13.6 |
| Female | 342 (73) |
| White | 408 (87) |
| Married | 337 (72) |
| Postsecondary education | 273 (58) |
| Household annual income, ≥ Can$50,000 | 233 (50) |
| Private insurance | 353 (75) |
| Urban residence | 394 (84) |
| Disease characteristics | |
| Disease duration, yrs | 0.4 ± 0.5 |
| SJC28, range 0–28, n = 452 | 5.9 ± 5.2 |
| TJC28, range 0–28, n = 448 | 7.2 ± 6.7 |
| PtGA, range 0–10, n = 418 | 4.9 ± 2.7 |
| PGA, range 0–10, n = 412 | 4.7 ± 2.3 |
| CDAI, range 0–76, n = 421 | 22.9 ± 14.1 |
| HAQ-DI, range 0–3, n = 467 | 1.1 ± 0.74 |
| HAQ pain index, range 0–3, n = 467 | 1.4 ± 0.85 |
| Fatigue score, range 0–10, n = 467 | 4.7 ± 3.1 |
| ESR, mm/h, n = 419 | 25.8 ± 21.6 |
| CRP, mg/l, n = 372 | 14.8 ± 23.0 |
| RF-positive | 293 (63) |
| Presence of erosions | 179 (38) |
| No. comorbidities | 3.1 ± 2.2 |
| Treatment profile | |
| Prior use of csDMARD | 260 (55) |
| Prior use of bDMARD | 25 (5) |
| Current csDMARD | 425 (91) |
| Current no. csDMARD | 2.0 ± 0.78 |
| Current bDMARD | 30 (6) |
| Subcutaneous | 24 (5) |
| Infusion | 6 (1) |
| Current oral corticosteroid use | 126 (27) |
| Current oral corticosteroid dose, mg/d | 7.1 ± 9.2 |
OBRI: Ontario Best Practices Research Initiative; SJC28: 28-joint swollen joint count; TJC28: 28-joint tender joint count; PtGA: patient’s global assessment; PGA: physician’s global assessment; CDAI: Clinical Disease Activity Index; HAQ-DI: Health Assessment Questionnaire–Disability Index; ESR: erythrocyte sedimentation rate; CRP: C-reactive protein; RF: rheumatoid factor; csDMARD: conventional synthetic disease-modifying antirheumatic drug; bDMARD: biologic DMARD.